GH Stack

Product name

GH Stack

Form

Research stack: 2 lyophilised vials

Solubility

Bacteriostatic water

Storage

Lyophilised: store at -20C, dry and light-protected. Reconstituted: 2-8C.

No third-party batch reports have been uploaded for this product yet. Reports are issued by independent labs after each manufacturing batch.

What is the GH Stack?

The GH Stack is a research bundle of two separate lyophilised reference peptides: CJC-1295 No DAC (5mg) in one vial and Ipamorelin (5mg) in a second vial. The compounds are not pre-mixed; each ships as its own sealed vial with its own certificate of analysis. Both are supplied strictly for laboratory research use only and are not licensed medicines.

What is in the GH Stack?

The bundle contains two distinct research peptides. CJC-1295 No DAC (Modified GRF 1-29) is a synthetic GHRH analogue, and Ipamorelin is a synthetic pentapeptide studied as a GHS-R agonist. Each is documented on its own product listing with its own chemistry and identifiers. The bundle introduces no new compound and is supplied as a convenience set of two reference materials.

Is this the GH stack people search for?

Yes. This CJC-1295 No DAC and Ipamorelin pairing is commonly referred to as the GH stack in the research community. Naming the search term identifies the listing; it does not describe what the compounds do. Both items remain research chemicals supplied for laboratory use only, with no human or veterinary application intended or implied.

Is the GH Stack legal in the UK?

Neither CJC-1295 No DAC nor Ipamorelin is a controlled drug under the Misuse of Drugs Act 1971, and neither is scheduled. The bundle is supplied strictly as research chemicals for laboratory and in-vitro investigation. It is not a licensed medicine and cannot be sold or supplied for human or veterinary consumption. The purchaser is responsible for lawful, compliant handling under their own obligations.

Is the GH Stack intended for human use?

No. The GH Stack is supplied strictly for laboratory research use only. Neither constituent is intended, labelled or sold for human or veterinary use, neither is a licensed medicine, and no human application is implied. The vials are reference compounds for non-clinical investigation. Any other use falls outside the terms of supply.

Have CJC-1295 No DAC and Ipamorelin been shown to be safe or effective together in humans?

No. The published work on each compound is conducted in pre-clinical and in-vitro model systems and investigates their separate receptor activity. None of it establishes a benefit, effect, safety profile or outcome in humans, and nothing establishes any combined effect of the two. They are supplied together only as a convenience bundle of separate reference materials, not as a tested combination.

Why are CJC-1295 No DAC and Ipamorelin studied together?

They are frequently referenced in the same literature because they act on different parts of the same research area: CJC-1295 No DAC is a GHRH analogue and Ipamorelin is a GHS-R agonist. People search for them as a pair, which is why this convenience bundle exists. This co-occurrence in the research area is not evidence of any combined effect in humans and is not a protocol or recommendation for any use.

Do the compounds in the GH Stack work better together?

No such claim is made. The two peptides are supplied together purely as a research convenience bundle of separate reference materials. Nothing here implies they synergise, amplify any response, or produce a benefit or outcome when supplied as a set. The reason they co-occur in the literature stays at research-area level only; see the CJC-1295 and Ipamorelin research monograph for the study-design detail.

What is the difference between CJC-1295 No DAC and Ipamorelin?

They are chemically and pharmacologically distinct molecules in the same GH-axis research area. CJC-1295 No DAC (Modified GRF 1-29) is a 29-amino-acid GHRH analogue, while Ipamorelin is a short pentapeptide studied as a selective GHS-R agonist acting at a different receptor. Each is documented in full on its own product page; the bundle simply supplies both as separate vials.

Is every vial in the GH Stack the same quality?

Each vial is treated as its own product and released only after independent testing. Purity is assessed by HPLC at 99% or higher per vial, and identity is confirmed against the expected mass for each compound. A batch-specific certificate of analysis accompanies each vial, so the CJC-1295 No DAC and the Ipamorelin can be verified independently on our certificates of analysis page.

How is the GH Stack supplied and reconstituted?

The GH Stack ships as two separate white to off-white lyophilised solids, one per sealed vial, despatched from the UK. For bench work each peptide is reconstituted independently with a research solvent such as bacteriostatic water; the vials are not combined as part of supply. The mg strength on each vial is a product specification, not a usage instruction, and no administration guidance is given or implied.

How should the GH Stack be stored?

Store both lyophilised vials at -20C, kept dry and protected from light, where the peptides are stable long term. Once reconstituted, hold the material at 2-8C and protect it from light. These are laboratory handling conditions for research reference compounds only and do not constitute any guidance for use in a human or animal.

Can I buy the GH Stack in the UK from Kovalabs?

Yes. Kovalabs supplies the GH Stack in the UK as two research chemicals for laboratory use only, despatched from the UK with a batch-specific certificate of analysis for each vial. It is sold as a convenience bundle of separate reference materials. It is not sold for human or veterinary consumption and neither constituent is a licensed medicine; the buyer is responsible for compliant handling.